ACIU · AC Immune SA — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on ACIU. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About ACIU · AC Immune SA
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Live Quote
HOLD (score -1) · 12-1 mom 35.4% · RSI 46.7 · below_both · -38.6% from high
Targets blend Wall Street consensus (4 analysts: low $6.77 / mean $8.66 / high $11.52) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
The investigation confirmed 4 Form 4 filings within the trigger window (June 11), but all were RSU/option grants (equity compensation at $0 cost basis) — not open-market purchases. The CEO's sole genuine P-code purchase ($31,425 on April 15 at $3.14) was effectively unwound by her sale of equivalent shares a month later at ~$2.79. No director made an open-market equity investment. AC Immune is a pre-revenue Swiss biotech burning cash with no commercial products; the stock sits near its 52-week low, down 35% YTD against a -34.75% period return. The primary bull catalyst — ABATE Phase 1b/2 data for ACI-24 in Alzheimer's — is expected Q2 2026 (data read still pending at time of investigation), but the CEO transition from Dr. Andrea Pfeifer to interim Chair Martin Zügel introduces operational uncertainty precisely when a key inflection point approaches.